Table 1. Patient and transplantation... | American Society of Hematology

Table 1.

Patient and transplantation characteristics

UPIN	Age, y	Sex	Stage at start of imatinib	Time on imatinib, mo	Best response to imatinib	Mutation type	Semiquantitative assessment of mutation*	Stage at mutation's detection	Status at Allo-SCT	Preparative regimen	Donor type	Source of stem cells
1	46	M	CE	24	CGCR	F486S	100%	AP	AP	BuCy	MUD	BM
2	50	M	AP	24	CHR	F317L	Mostly	CP	CP	BuCy	MRD	BM
3	48	F	CE	7	CGCR	L248V	Low level	CP	CP	BuCy	MRD	BM
4	26	F	CE	3	CHR	Y253H	Mixed	BP	CHR	BuCy	MRD	PB
5	54	M	Ph⁺ ALL	8	CGCR	Q252H	Low level	Ph⁺ ALL	MMR	FM	MUD	BM
6	41	M	CE	24	CGCR	T315I	100%	AP	AP	BuCy	MUD	BM
7	63	M	CP	21	MCR	T315I	100%	CP	MCR	FM	MUD	BM
8	37	M	CE	14	MinorCG	G250E	100%	AP	AP	BuCy	MUD	BM
9	31	M	AP	14	CHR	F359V	100%	AP	AP	FM	MRD	PB
10	46	M	AP	5	MinorCG	E255K	100%	BP	CHR	BuFlu	MRD	PB

UPIN	Age, y	Sex	Stage at start of imatinib	Time on imatinib, mo	Best response to imatinib	Mutation type	Semiquantitative assessment of mutation*	Stage at mutation's detection	Status at Allo-SCT	Preparative regimen	Donor type	Source of stem cells
1	46	M	CE	24	CGCR	F486S	100%	AP	AP	BuCy	MUD	BM
2	50	M	AP	24	CHR	F317L	Mostly	CP	CP	BuCy	MRD	BM
3	48	F	CE	7	CGCR	L248V	Low level	CP	CP	BuCy	MRD	BM
4	26	F	CE	3	CHR	Y253H	Mixed	BP	CHR	BuCy	MRD	PB
5	54	M	Ph⁺ ALL	8	CGCR	Q252H	Low level	Ph⁺ ALL	MMR	FM	MUD	BM
6	41	M	CE	24	CGCR	T315I	100%	AP	AP	BuCy	MUD	BM
7	63	M	CP	21	MCR	T315I	100%	CP	MCR	FM	MUD	BM
8	37	M	CE	14	MinorCG	G250E	100%	AP	AP	BuCy	MUD	BM
9	31	M	AP	14	CHR	F359V	100%	AP	AP	FM	MRD	PB
10	46	M	AP	5	MinorCG	E255K	100%	BP	CHR	BuFlu	MRD	PB

UPIN indicates patient unique identifier; M, male; CE, early chronic phase; CGCR, complete cytogenetic response; AP, accelerated phase; BuCy, intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses and cyclophosphamide 60 mg/kg for 2 days; MUD, matched unrelated donor; BM, bone marrow; CHR, complete hematologic response; CP, chronic phase; MRD, matched related donor; F, female; BP, blast phase; PB, peripheral blood; Ph⁺ ALL, Philadelphia-positive acute lymphocytic leukemia; MMR, major molecular response; FM, fludarabine 30 mg/m² for 4 days and melphalan 140 mg/m²; MCR, major cytogenetic response; MinorCG, minor cytogenetic response; and BuFlu, fludarabine 40 mg/m² for 4 days, intravenous busulfan 130 mg/m² for 2 days, and antithymocyte globulin.

Estimate of proportion of mutation-bearing cells.

View Large

This Feature Is Available To Subscribers Only